Imaging agent linked to false positives in Crohn's disease diagnosis

09/30/2008 | HealthImaging.com

The OctreoScan imaging agent, when used in neuroendocrine tumor detection, may cause false positive results in diagnosing Crohn's disease, Spanish researchers said. In a study of a patient suspected to have an ileal carcinoid tumor, the researchers obtained a positive OctreoScan and reported Crohn's disease after performing surgery and histological analysis. Immunohistochemical studies, however, did not reveal any somatostatin receptors, the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX